Krystal Biotech, Inc. - $KRYS STOCK NEWS

Krystal Biotech, Inc. reported $45.3 million in net product revenue for 1Q 2024. The company is focused on delivering genetic medicines for rare diseases like Dystrophic Epidermolysis Bullosa. With a strong financial position and positive performance in clinical trials, Krystal Biotech is poised for growth. Key developments include progress with VYJUVEK, successful clinical studies in Japan, and ongoing trials for cystic fibrosis and alpha-1 antitrypsin deficiency treatments. The company also received FDA Fast Track Designation for inhaled KB707 for lung tumors. Financially, the company recorded $622.3 million in cash and investments with a net income of $0.9 million for 1Q 2024.

Krystal Biotech announced their participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting where they will present new preclinical data on their HSV-1 based vector platform for back of the eye gene delivery. The poster presentation will focus on localized delivery to the posterior of the eye, with details about the presenter, date, time, and abstract number. The poster will be available both at the conference and online on the Investor section of the Company's website.

Krystal Biotech, a commercial-stage biotechnology company, will report its first quarter 2024 financial results on May 6, 2024. The Company's management will host a conference call and webcast to discuss the results and provide a business update.

Krystal Biotech announced the dosing of the first patient in a Phase 1 clinical trial for inhaled KB707, a therapy for locally advanced or metastatic solid tumors of the lung. This therapy has the potential to expand the clinical utility of cytokine therapy for difficult-to-treat tumors. The company also received Fast Track Designations for inhaled and intratumoral KB707 from the FDA.

Krystal Biotech, Inc. (KRYS) presents new preclinical data on intratumoral delivery of IL-12 and IL-2, showing enhanced local and systemic effector T-cell responses in a cold tumor preclinical model at AACR 2024 Annual Meeting.

Krystal Biotech, Inc. (KRYS) will participate in the TD Cowen 44th Annual Health Care Conference in Boston. Chairman and CEO Krish S. Krishnan will host a fireside chat and investor meetings. A webcast of the presentation will be available on the Company's website.

Krystal Biotech reports strong financial results with $42.1M in net product revenue in 4Q and $50.7M for the year, FDA alignment for B-VEC eyedrop formulation, and initiation of Phase 1 KB408 trial for AATD treatment.

Krystal Biotech, Inc. (KRYS) will release its Q4 and full year 2023 financial results on February 26, 2024, followed by a webcast for financial updates. An investor webcast will also be held on the same day at 8:30 am ET.

Krystal Biotech, Inc. receives FDA Fast Track Designation for inhaled KB707 in the treatment of solid tumors with pulmonary metastases. Phase 1 clinical trial (KYANITE-1) expected to start in 1H 2024.